Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company which engineers targeted immunotherapies, seeking to improve patient outcomes through the power of innate immunity. Affimed’s fit-for-purpose ROCK® platform allows innate immune engagers to be designed for specific patient populations. We are developing single and combination therapies to treat cancers.
To strengthen our highly motivated Research & Development Team in Heidelberg, Germany, we are looking for a
Reference No. R2202
For any queries, please contact Susanne Hering (Tel: +49 6221 6743 675, e-mail: firstname.lastname@example.org).